Twist Bioscience (TWST) Receivables (2018 - 2026)

Twist Bioscience (TWST) has 9 years of Receivables data on file, last reported at $72.5 million in Q1 2026.

• Receivables for Q1 2026 came in at $72.5 million, up 41.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $72.5 million (up 41.08% YoY), and the FY2025 annual result was $57.3 million, up 55.17% from the prior year.
• Receivables grew to $72.5 million in Q1 2026 per TWST's latest filing, from $62.4 million in the prior quarter.
• Over five years, Receivables peaked at $72.5 million in Q1 2026 and troughed at $34.6 million in Q2 2024.
• A 5-year average of $47.8 million and a median of $46.9 million in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2024: Receivables soared 1769.66% in 2022, then declined 28.16% in 2024.
• A 5-year view of Receivables shows it stood at $49.7 million in 2022, then retreated by 23.82% to $37.9 million in 2023, then grew by 8.71% to $41.2 million in 2024, then soared by 51.54% to $62.4 million in 2025, then grew by 16.33% to $72.5 million in 2026.
• Business Quant data shows TWST's Receivables at $72.5 million in Q1 2026, $62.4 million in Q4 2025, and $57.3 million in Q3 2025.